Analysts Set COMPASS Pathways plc (NASDAQ:CMPS) PT at $20.20

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been given a consensus recommendation of “Buy” by the six research firms that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $20.20.

A number of equities research analysts have weighed in on CMPS shares. Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They issued a “buy” rating and a $11.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of COMPASS Pathways in a research note on Monday, May 12th. Cantor Fitzgerald upgraded shares of COMPASS Pathways to a “strong-buy” rating in a report on Tuesday, May 13th. Finally, Canaccord Genuity Group dropped their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 28th.

Institutional Trading of COMPASS Pathways

Several institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP acquired a new position in shares of COMPASS Pathways in the fourth quarter worth about $11,714,000. Nantahala Capital Management LLC lifted its position in shares of COMPASS Pathways by 182.9% in the 1st quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company’s stock valued at $8,092,000 after acquiring an additional 1,829,232 shares in the last quarter. Vivo Capital LLC boosted its stake in COMPASS Pathways by 109.1% in the 1st quarter. Vivo Capital LLC now owns 3,362,385 shares of the company’s stock worth $9,616,000 after purchasing an additional 1,754,385 shares during the period. Altium Capital Management LLC acquired a new position in COMPASS Pathways in the 4th quarter worth approximately $5,384,000. Finally, Woodline Partners LP grew its position in COMPASS Pathways by 279.9% during the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company’s stock worth $5,019,000 after purchasing an additional 1,292,927 shares in the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

COMPASS Pathways Stock Performance

CMPS opened at $4.34 on Monday. The business has a 50 day moving average price of $3.41 and a two-hundred day moving average price of $3.94. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company has a market capitalization of $402.96 million, a price-to-earnings ratio of -1.97 and a beta of 2.27. COMPASS Pathways has a 1-year low of $2.49 and a 1-year high of $8.54.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.03. Research analysts predict that COMPASS Pathways will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.